METHOD DEVELOPMENT

TAAB works with you as a bioanalytical contract research organization to develop assays on the most appropriate technology platform. Prior to starting any method development, we review and discuss with you the assay requirements and intended use, such as:

• Lead Optimization vs. Candidate Selection vs. Regulated Bioanalysis

• Ultra-high-performance liquid chromatography–mass spectrometry (UPLC MS/MS) for small molecule drug candidates and their potential metabolites

• Ligand Binding Assay (LBA) or hybrid UPLC MS/MS for peptide and protein drugs

• Hybridization LBA or hybridization HPLC fluorescence or UPLC coupled to high-resolution mass spectrometry (UPLC HRMS) or UPLC-MS/MS or HPLC ultraviolet (UV) for oligonucleotide based drugs

• Reverse Transcription – Quantitative Polymerase Chain Reaction (RT qPCR/qPCR) for mRNA (biotherapeutics and viral or plasmid vectors)

More information coming soon...